Related Posts
- CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression
Background Despite significant progress in the development of T cell-engaging therapies for various B-cell malignancies,…
- 1024 CLN-978, a novel CD19/CD3/HSA T cell engager with extended serum half-life, is effective against lymphoma cells expressing very low levels of CD19
Background T cell therapies targeting the B cell antigen CD19 have profoundly changed the way…
- CD22 CAR T-Cell Therapy in LBCL After CD19 CAR T Failure
KEY TAKEAWAYS The phase 1 trial aimed to investigate the efficacy and safety of CD22-directed…